ArticleJournal of pharmacy & bioallied sciences2025
Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alopecia areata (AA) is an autoimmune condition marked by non-scarring hair loss. Materials and Method: In this prospective observational study, we enrolled 50 pediatric patients with moderate-to-severe alopecia areata. Participants received oral tofacitinib for 24 weeks. Clinical efficacy was assessed using the Severity of Alopecia Tool (SALT) score. Secondary outcomes included time to hair regrowth, patient/parent satisfaction, and Paediatric Quality of Life Inventory (PedsQL) scores. Result: Forty-five participants completed the 24-week study. A significant decrease in SALT score from baseline (mean 66.2 ± 8.1) to week 24 (mean 25.7 ± 9.2) was observed ( Conclusion: Tofacitinib demonstrated a favorable risk-benefit profile for treating moderate-to-severe pediatric alopecia areata over 24 weeks. These findings support the potential of JAK inhibitors as a therapeutic option in children with recalcitrant disease, although long-term safety and relapse rates warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.